KURA vs UNH

Kura Oncology remains a highly speculative, high-risk, high-reward investment for 10x growth potential, with its core thesis centered on KOMZIFTI's market penetration. The Q4 2025 revenue of $17.34M, while higher than the previously reported early KOMZIFTI sales, still significantly missed the $74.52M consensus estimate, deepening concerns about commercialization execution. However, the initial ma...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...